<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2535">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04820751</url>
  </required_header>
  <id_info>
    <org_study_id>25584</org_study_id>
    <nct_id>NCT04820751</nct_id>
  </id_info>
  <brief_title>Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial</brief_title>
  <official_title>Cyproheptadine in Severe COVID-19 : A Unblinded Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ciusss de L'Est de l'Île de Montréal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covid-19 Early Treatment Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ciusss de L'Est de l'Île de Montréal</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controled open label clinical trial is to evaluate the effect of&#xD;
      Cyproheptadine on the clinical course of patients presenting a severe SARS-COV 2 pneumonia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational and biochemical studies have identified an interesting pathway in the&#xD;
      pathophysiology of certain clinical-biological characteristics of COVID-19, linked to an&#xD;
      excess of serotonin. We hypothesize that the antagonism of the action of serotonin could&#xD;
      improve the clinical course of patients most severely affected by COVID-19.&#xD;
&#xD;
      One such antagonist of serotonin with a long track record of safety and tolerability is&#xD;
      cyproheptadine. Cyproheptadine acts as an antagonist of 5-hydroxytryptamine (5HT=serotonin)&#xD;
      receptor subtype 2 as well as histamine-1 receptor. Many of the potent effects of serotonin&#xD;
      on lung vascular tone, respiratory rate, and systemic vascular beds are mediated by 5-HT&#xD;
      receptor subtype 2.&#xD;
&#xD;
      Investigators will randomize approximately 200 participants, aged 18 and older, who have&#xD;
      tested positive for COVID-19 and who will be hospitalized at Santa Cabrini Hospital in&#xD;
      Montreal, Quebec, Canada, presenting a severe form of covid-pneumonia-19 requiring&#xD;
      supplemental oxygen.&#xD;
&#xD;
      Study eligibility of all participants will be assessed first. Once a participant is confirmed&#xD;
      eligible and consented, they will participate in the study.&#xD;
&#xD;
      Participants will be randomly assigned (1: 1) to either take cyproheptadine 8 mg by mouth&#xD;
      three times a day for 5 days and receive standard care or receive standard care alone.&#xD;
&#xD;
      The dose will be adjusted according to the glomerular filtration rate.&#xD;
&#xD;
      On D1, D3, D5, D7 and D10 since randomization, participant's vital signs (including SpO2,&#xD;
      respiratory rate, FiO2 or oxygen flow, heart rate, blood pressure and temperature), blood&#xD;
      creatinine, bilirubin, CRP, LDH, Dimers and platelets the count will be evaluated. Any&#xD;
      adverse event will be assessed daily and documented.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 10, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Length of hospitalization</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Need mechanical ventilation (Non invasive or Invasive)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospitalization in the intensive care unit</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA Score</measure>
    <time_frame>At Day 1,3,5,7,10 after randomization</time_frame>
    <description>Sequential Organ Failure Min Score 0-Max score 24 Higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>At Day 1,3,5,7,10 after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Rate</measure>
    <time_frame>At Day 1,3,5,7,10 after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spo2/FiO2 and ROX ratio</measure>
    <time_frame>At Day 1,3,5,7,10 after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP level</measure>
    <time_frame>At Day 1,3,5,7,10 after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDH level</measure>
    <time_frame>At Day 1,3,5,7,10 after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-Dimere level</measure>
    <time_frame>At Day 1,3,5,7,10 after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet count</measure>
    <time_frame>At Day 1,3,5,7,10 after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Viral Pneumonia</condition>
  <condition>Serotonin Syndrome</condition>
  <condition>Platelet Dysfunction</condition>
  <arm_group>
    <arm_group_label>Cyproheptadine and standard care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Start Cyproheptadine 8mg three times a day during 5 days. Dose will be reduced to 4mg three times a day if GFR inferior to 30ml/min/1.73m²&#xD;
Standard management of COVID-19 infection according to current international guidelines</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard management of COVID-19 infection according to current international guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyproheptadine Hydrochloride 4 MG</intervention_name>
    <description>Cyproheptadine associated to standard care</description>
    <arm_group_label>Cyproheptadine and standard care</arm_group_label>
    <other_name>Standard Care</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women age 18 or older&#xD;
&#xD;
          -  Hospitalized and requiring medical care for COVID-19&#xD;
&#xD;
          -  Presenting respiratory failure cause by COVID 19 requiring oxygen and/or mechanical&#xD;
             ventilation support&#xD;
&#xD;
          -  With radiographic evidence of pulmonary infiltrate&#xD;
&#xD;
          -  Able to give informed consent or, if unable to do so regarding the medical condition,&#xD;
             having relatives able of consenting for the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Patients with pre-existing terminal condition with life expectancy &lt; 6 months&#xD;
&#xD;
          -  Patients with pre-existing severe lung disease requiring home O2&#xD;
&#xD;
          -  History of seizure disorder&#xD;
&#xD;
          -  History of adverse reaction to antihistamines or to Cyproheptadine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe Rola, MD</last_name>
    <phone>514 252-6000</phone>
    <email>philippe.rola@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexandre Noel, MD</last_name>
    <phone>514 252-6000</phone>
    <email>alexandre.noel.1@umomtreal.ca</email>
  </overall_contact_backup>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid 19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Malignant Carcinoid Syndrome</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Serotonin Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyproheptadine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

